Clinical trial · people

Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgery

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This adds early evidence that thymosin alpha-1 has been tested alongside cancer immunotherapy and chemotherapy before stomach cancer surgery, but it does not show what the peptide adds on its own.

Kind
Clinical trial
Studied in
People
Number studied
30
Published
2026
Journal
BMC Med

What they tested

Researchers tested whether adding thymalfasin (thymosin alpha-1) to serplulimab, an anti-PD-1 immune drug, plus SOX chemotherapy (S-1 and oxaliplatin) before surgery works and is safe in locally advanced stomach and gastroesophageal junction cancer.

How the study was done

A prospective phase II trial in 30 adults aged 18-75 with stage III stomach or gastroesophageal junction adenocarcinoma, all given three 21-day cycles of serplulimab plus SOX and 9 weeks of thymalfasin, then surgery to remove the stomach. Every patient got the same treatment, with no comparison group.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

All 30 patients had minimally invasive surgery, and 30.0% (9/30) had a pathological complete response, meaning no cancer was found in the removed tissue. A major pathological response was seen in 56.7% (17/30), 63.3% (19/30) had no cancer in their lymph nodes after treatment, and 80.0% (24/30) had their lymph node stage lowered. Over a median follow-up of 14.0 months, one patient relapsed and no one died. Side effects of any grade occurred in 93.3%, grade 3 or worse in 26.7%, and immune-related side effects in 23.3%, while blood tests showed shifts in immune cells such as more CD8+ T cells.

What it doesn’t show

With no group treated without thymalfasin, the trial cannot separate its effect from that of serplulimab and chemotherapy. It was small, follow-up was about 14 months, and the immune changes were measured in blood, not shown to cause the tumor responses.

The paper

Xu et al. Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. BMC Med. 2026.

The compound

More studies on Thymosin Alpha-1

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo